

Susanne Kossatz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3309225/susanne-kossatz-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

1,144
citations

19
h-index

32
g-index

57
ext. papers

1,524
ext. citations

7.2
avg, IF

4.38
L-index

#	Paper	IF	Citations
53	Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes.. <i>Inorganic Chemistry</i> , 2022 ,	5.1	1
52	DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.. <i>Cancers</i> , 2022 , 14,	6.6	1
51	Identification of adeno-associated virus variants for gene transfer into human neural cell types by parallel capsid screening.. <i>Scientific Reports</i> , 2022 , 12, 8356	4.9	2
50	Combined PARP1-targeted nuclear contrast and reflectance contrast enhances confocal microscopic detection of basal cell carcinoma. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	2
49	There is a world beyond $\alpha\beta$ -integrin: Multimeric ligands for imaging of the integrin subtypes $\alpha\beta$, $\alpha\delta$, $\alpha\epsilon$, and $\alpha\zeta$ by positron emission tomography. <i>EJNMMI Research</i> , 2021 , 11, 106	3.6	0
48	PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 941-948	8.9	1
47	The organometallic ferrocene exhibits amplified anti-tumor activity by targeted delivery via highly selective ligands to $\alpha\beta$, $\alpha\delta$, or $\alpha\zeta$ integrins. <i>Biomaterials</i> , 2021 , 271, 120754	15.6	3
46	RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field. <i>Cancers</i> , 2021 , 13,	6.6	20
45	A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3618-3630	8.8	6
44	Frischer Wind β Integrine. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2021 , 44, 152-159	0.1	
43	NIR Fluorescence Imaging of Colon Cancer with cRGD-ZW800-1-Letter. <i>Clinical Cancer Research</i> , 2021 , 27, 4937	12.9	0
42	PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" $\alpha\beta$ with Ga-68-Trivehexin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 1	8.8	3
41	Click-Chemistry (CuAAC) Trimerization of an $\alpha\beta$ Integrin Targeting Ga-68-Peptide: Enhanced Contrast for in-Vivo PET Imaging of Human Lung Adenocarcinoma Xenografts. <i>ChemBioChem</i> , 2020 , 21, 2836-2843	3.8	12
40	Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. <i>Nature Biomedical Engineering</i> , 2020 , 4, 272-285	19	25
39	Fluorescence-guided resection of tumors in mouse models of oral cancer. <i>Scientific Reports</i> , 2020 , 10, 11175	4.9	8
38	Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
37	Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[F]fluoro-d-glucose positron emission tomography in oral cancer imaging. <i>Nuclear Medicine and Biology</i> , 2020 , 84-85, 80-87	2.1	9

36	Preclinical and first-in-human-brain-cancer applications of [F]poly (ADP-ribose) polymerase inhibitor PET/MR. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa119	0.9	5
35	Optical Imaging Modalities: Principles and Applications in Preclinical Research and Clinical Settings. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1419-1427	8.9	20
34	An Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 433-436	8.9	14
33	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. <i>Clinical Cancer Research</i> , 2020 , 26, 2871-2881	1.9	37
32	Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1743-1752	8.9	8
31	Acid specific dark quencher QC1 pHLP for multi-spectral optoacoustic diagnoses of breast cancer. <i>Scientific Reports</i> , 2019 , 9, 8550	4.9	12
30	Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. <i>Clinical Cancer Research</i> , 2019 , 25, 4332-4342	12.9	15
29	Fluorescence Imaging of Peripheral Nerves by a Na1.7-Targeted Inhibitor Cystine Knot Peptide. <i>Bioconjugate Chemistry</i> , 2019 , 30, 2879-2888	6.3	10
28	Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 166-173	6.7	26
27	Target engagement imaging of PARP inhibitors in small-cell lung cancer. <i>Nature Communications</i> , 2018 , 9, 176	17.4	53
26	PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1225-1233	8.9	28
25	Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1316-1320	8.9	9
24	Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening. <i>Molecular Imaging</i> , 2018 , 17, 1536012118808644	3.7	15
23	Discriminating radiation injury from recurrent tumor with [F]PARPi and amino acid PET in mouse models. <i>EJNMMI Research</i> , 2018 , 8, 59	3.6	9
22	Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. <i>Immunity</i> , 2018 , 49, 819-828.e6	32.3	95
21	Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. <i>Bioconjugate Chemistry</i> , 2018 , 29, 3776-3782	6.3	12
20	Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. <i>Cancer Research</i> , 2017 , 77, 2112-2123	10.1	18
19	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E7441-E7449	11.5	22

18	cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. <i>Dalton Transactions</i> , 2017 , 46, 11925-11941	4.3	8
17	Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent. <i>Molecular Imaging</i> , 2017 , 16, 1536012117723786	3.7	11
16	Synthesis of a Fluorescently Labeled Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting. <i>ACS Medicinal Chemistry Letters</i> , 2017 , 8, 720-725	4.3	20
15	Molecular Imaging of PARP. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1025-1030	8.9	57
14	Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. <i>Molecular Imaging and Biology</i> , 2016 , 18, 386-92	3.8	48
13	Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0147752	3.7	22
12	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. <i>Scientific Reports</i> , 2016 , 6, 21371	4.9	46
11	Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. <i>Molecular Imaging and Biology</i> , 2015 , 17, 848-55	3.8	46
10	Radioiodinated PARP1 tracers for glioblastoma imaging. <i>EJNMMI Research</i> , 2015 , 5, 123	3.6	33
9	Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery. <i>Breast Cancer Research</i> , 2015 , 17, 66	8.3	183
8	High therapeutic efficiency of magnetic hyperthermia in xenograft models achieved with moderate temperature dosages in the tumor area. <i>Pharmaceutical Research</i> , 2014 , 31, 3274-88	4.5	100
7	Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 641-50	5.8	12
6	Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. <i>Biomaterials</i> , 2013 , 34, 5172-80	15.6	21
5	Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties. <i>EJNMMI Research</i> , 2013 , 3, 75	3.6	4
4	Optical imaging of CCK ₂ /gastrin receptor-positive tumors with a minigastrin near-infrared probe. <i>Investigative Radiology</i> , 2011 , 46, 196-201	10.1	11
3	A Phase I Study of a PARP1-targeted Topical Fluorophore for the Detection of Oral Cancer		1
2	Targeted brain tumor radiotherapy using an Auger emitter		2
1	PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers [first-in-human results]		6

